Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Hemadsorción para mejorar la eliminación de fármacos en intoxicaciones (MATRIX)

18 de septiembre de 2026 actualizado por: Universitair Ziekenhuis Brussel

In this trial the investigators assess the effectiveness of applying a hemadsorber (cytosorb®) in removing benzodiazepines or tricyclic antidepressants in intoxicated patients admitted to ICU with prolonged impaired consciousness. This is a one arm interventional investigation where a hemadsorption filter is applied in patients fulfilling inclusion criteria 8 hours after admission. Plasma titer of the neurodepressing drug will be collected sequentially both before and after start of hemadsorption to evaluate the speed of drug elimination before and after application of a hemadsorption filter. Pre- and post filter titers will be obtained to evaluate adsorbability and to evaluate time to saturation of the filter.

Descripción general del estudio

Estado

Reclutamiento

Intervención / Tratamiento

Descripción detallada

In this prospective interventional study with medical device, the investigotors would include 18 patients admitted to ICU after an intoxication with a quantifiable neurodepressing drugs (type benzodiazepines or tricyclic antidepressants) and with impaired consciousness defined as need for intubation or need for Flumazenil to prevent intubation. Naloxone is administered per standard of care to identify if opioid intoxications is the main reason of neurodepression. Patients requiring mechanical ventilation for other reasons than impaired consciousness due to this intoxication or indication for prolonged use of sedatives are excluded.

Patients with at least one risk factor for delayed drug elimination (Chronic kidney disease G3b or CHILD-Pugh B or C) and persisting impaired consciousness after eight hours (including patients with persisting need for flumazenil) and having 5 plasma titers of the neurodepressing drug with intervals of 2 hours will be initiated on a hemadsorption filter after contact between the treating team and either dr. Michaël Mekeirele or dr. Tim Balthazar to verify inclusion criteria. Patients fulfilling inclusion criteria but lacking the 5 plasma titers will get additional plasma titers with intervals of 2 hours until 5 plasma titers are obtained. If these patients still fulfill inclusion criteria at that time then a hemadosorption filter will be initiated.

After starting hemadsorption a plasma titer pre- and post filter will be obtained after 15 minutes and every 4 hours after starting hemadsorption for the first 24 hours. After this timepoint additional plasma titers will be obtained every 24 hours until stopping hemadsorption or normalisation of the plasma titer.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

18

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Brussels Capital
      • Brussels, Brussels Capital, Bélgica, 1090
        • Reclutamiento
        • Universitair Ziekenhuis Brussel
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Michaël Mekeirele, Medical Doctor

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. older than18 years
  2. Admission to ICU
  3. GCS < 8 or requiring Flumazenil 8 hours after hospital admission
  4. Having an intoxication with a benzodiazepine or tricyclic antidepressant that we can measure/quantify
  5. Having a risk factor for delayed drug elimination defined as either Cirrhosis CHILD B/C or chronic kidney insufficiency KDIGO 3b or worse

Exclusion Criteria:

  1. Pregnant patient
  2. Patients in chronic dialysis before admission
  3. Need for mechanical ventilation for other reasons than intoxications (e.g. pneumonia, neurotrauma)
  4. Concomitant pathology requiring continued intravenous sedation
  5. Known history of seizures
  6. Contra-indication to heparin use
  7. DNR restricting the use of mechanical ventilation or dialysis

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Hemadsorption

Hemadsorption via a dialysis catheter will be performed in patients who are unconscious due to an intoxication with quantifiable benzodiazepines or tricyclic antidepressants 8 hours after admission. Before and after application fo this hemadsorption filter plasma titers of this drug will be obtained. After application of the hemadsorption filter pre- and post-filter titers will be obtained.

Plasma titers neurodepressing drug:

  • At admission to the hospital (standard of care)
  • 2 hours after admission (+/- 15 minutes)
  • 4 hours after admission (+/- 15 minutes)
  • 6 hours after admission (+/- 15 minutes)
  • 8 hours after admission (+/- 15 minutes)
  • Just before start hemadsorption

Hemadsorption via dialysis catheter in patients still fulfilling inclusion criteria 8 hours after admission.

Subsequent plasma titers pre- and post-hemadosorption filter:

  • 15 minutes after start of hemadsorption (+ 15 minutes)
  • 4 hours after start of hemadsorption (+/- 15 minutes)
  • 8 hours after start of hemadsorption (+/- 15 minutes)
  • 12 hours after start of hemadsorption (+/- 15 minutes)
  • 16 hours after start of hemadsorption (+/- 15 minutes)
  • 20 hours after start of hemadsorption (+/- 15 minutes)
  • 24 hours after start of hemadsorption (+/- 15 minutes)
  • Every other 24 hours until cessation of hemadsorption or normalization of the plasma titer (+/- 15 minutes)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Difference in time to upper limit of normal of the dosed drug with versus without hemadsorption
Periodo de tiempo: From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days

Based on plasma titers before start of hemadsorption the half life of the drug can be calculated. A theoretical intersection with the upper boundary of normal of the intoxicated drug plasma titer can be calculated. This will be statistically compared to the real time of attaining this titer after start of hemadsorption.

From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Adsorbability of the individual neurodepressing drugs
Periodo de tiempo: From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days

Comparing the pre- and post filter titer of the neurodepressing drug the adsorbability can be observed.

From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days
Time to saturation of hemadsorption filter
Periodo de tiempo: From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days

Comparing the pre- and post filter titer of the neurodepressing drug the time to saturation can be observed

From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days
Catheter related complications
Periodo de tiempo: From enrollment to the removal of the dialysis catheter +/- 3 days

Catheter related complications (eg bleeding, infection) will be noted

From enrollment to the removal of the dialysis catheter +/- 3 days
Seizures during hemadsorption therapy
Periodo de tiempo: From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days

Seizures during hemadsorption therapy will be noted

From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days
Bleeding during hemadsorption therapy
Periodo de tiempo: From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days

Bleeding during hemadsorption therapy will be noted

From enrollment to the end of treatment (cesation hemadsorption) +/- 3 days
Cost effectiveness of applying a Cytosorb® hemadsorption filter
Periodo de tiempo: From enrollment to discharge from ICU (+/- 1 week)

Duration of ICU stay, duration of ventilation, cost of a hemadsorption filter and disposables amongst others will be used for an evaluation of cost effectiveness

From enrollment to discharge from ICU (+/- 1 week)
Duration mechanical ventilation
Periodo de tiempo: From enrollment to extubation (+/- 3 days)

Time to extubation and stop of flumazenil will be noted

From enrollment to extubation (+/- 3 days)
Duration ICU stay
Periodo de tiempo: From enrollment to discharge from ICU (+/- 1 week)

Time to discharge will be noted

From enrollment to discharge from ICU (+/- 1 week)
Need and duration vasopressors
Periodo de tiempo: From enrollment to stop of vasopressors (+/- 3 days)

Time untill discontinuation of vasopressors will be noted

From enrollment to stop of vasopressors (+/- 3 days)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Michaël Mekeirele, Medical Doctor, Universitair Ziekenhuis Brussel

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de mayo de 2025

Finalización primaria (Estimado)

1 de diciembre de 2028

Finalización del estudio (Estimado)

1 de enero de 2029

Fechas de registro del estudio

Enviado por primera vez

2 de abril de 2025

Primero enviado que cumplió con los criterios de control de calidad

3 de abril de 2025

Publicado por primera vez (Actual)

10 de abril de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

23 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CIV-24-12-050174

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Single center study

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir